Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Fulcrum Therapeutics Inc

FULC
Current price
3.96 USD -0.06 USD (-1.49%)
Last closed 4.03 USD
ISIN US3596161097
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 216 294 192 USD
Yield for 12 month -18.69 %
1Y
3Y
5Y
10Y
15Y
FULC
21.11.2021 - 28.11.2021

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. It has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Address: 26 Landsdowne Street, Cambridge, MA, United States, 02139

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

5.29 USD

P/E ratio

Dividend Yield

Current Year

+2 805 000 USD

Last Year

+6 342 000 USD

Current Quarter

Last Quarter

+80 000 000 USD

Current Year

+2 805 000 USD

Last Year

+3 928 000 USD

Current Quarter

Last Quarter

+62 739 000 USD

Key Figures FULC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -30 880 000 USD
Operating Margin TTM 65.62 %
PE Ratio
Return On Assets TTM -6.89 %
PEG Ratio
Return On Equity TTM -7.37 %
Wall Street Target Price 5.29 USD
Revenue TTM 81 630 000 USD
Book Value 3.8 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 8990.9 %
Dividend Yield
Gross Profit TTM -70 440 000 USD
Earnings per share -0.29 USD
Diluted Eps TTM -0.29 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY
Profit Margin -24.79 %

Dividend Analytics FULC

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History FULC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation FULC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 117.3999
Price Sales TTM 2.6497
Enterprise Value EBITDA -3.0945
Price Book MRQ 0.8365

Financials FULC

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators FULC

For 52 weeks

2.86 USD 13.7 USD
50 Day MA 3.47 USD
Shares Short Prior Month 4 970 723
200 Day MA 6.89 USD
Short Ratio 7.67
Shares Short 4 678 092
Short Percent 9.92 %